Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| HQ Science Ltd. | 2024 | Grant | $264K | Cheshunt |
| Sparian Biosciences | 2024 | Grant | $19.5M | New York |
| NextStep Robotics | 2024 | Seed | $200K | Baltimore |
| Brixton Biosciences | 2024 | Grant | $2.0M | Cambridge |
| YoungHeartValve | 2024 | Grant | $2.8M | Atlanta |
| Pip Care | 2024 | Series A | $5.0M | New York |
| Allyx Therapeutics | 2024 | Grant | $3.3M | New Haven |
| Modality.AI | 2024 | Seed | $571K | San Francisco |
| Resvita Bio | 2024 | Grant | $2.0M | Berkeley |
| Lasarrus | 2024 | Grant | $499K | Baltimore |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 126 | HQ Science Ltd. | Grant | $264K | Cheshunt, United Kingdom |
| 127 | Sparian Biosciences | Grant | $19.5M | New York, United States |
| 128 | NextStep Robotics | Seed | $200K | Baltimore, United States |
| 129 | Brixton Biosciences | Grant | $2.0M | Cambridge, United States |
| 130 | YoungHeartValve | Grant | $2.8M | Atlanta, United States |
| 131 | Pip Care | Series A | $5.0M | New York, United States |
| 132 | Allyx Therapeutics | Grant | $3.3M | New Haven, United States |
| 133 | Modality.AI | Seed | $571K | San Francisco, United States |
| 134 | Resvita Bio | Grant | $2.0M | Berkeley, United States |
| 135 | Lasarrus | Grant | $499K | Baltimore, United States |
HQ Science is a biotechnology company at the forefront of molecular diagnostics innovation.
Sparian Biosciences is a biopharmaceutical company.
NextStep Robotics is developing the first effective treatment option for foot drop to help stroke survivors.
Brixton Biosciences is a clinical-stage life sciences company that develops therapies for chronic and acute pain.
YoungHeartValve is a Polymeric Hyaluronan-Enhanced Transcatheter Aortic Valves which were developed by engineers by inspiration from nature.
Pip Care provides a personalized surgical journey platform, optimizing perioperative care processes and supporting patients and care teams.
Allyx Therapeutics is a clinical-stage biotechnology company that develops therapies to reverse neurodegeneration.
Self-Driven Neurological Assessments
Resvita Bio develops and manufactures engineered probiotics for use in treatment if skin related diseases including cancer.
Lasarrus develops devices for patients with chronic obstructive pulmonary disease.
EndoTheia is a medical equipment manufacturing firm that supplies the next generation of flexible endoscopic devices.
Medical Device Research and Development
Xylyx Bio creates effective science-based solutions for the benefit of human life and health.
ONL Therapeutics is a biopharmaceutical company dedicated to protecting vision through the protection of photoreceptors.
Evoq Therapeutics is a cancer immunotherapy company that provides disease-specific immune modulators.
Reduce clinical variation and gain 10x efficiencies – continuous insights and monitoring
This company is a Boston-based biopharmaceutical company developing immune-based approaches.
Penderia Technologies is a new medical device company that specializes in creative ways to treat orthopedic ailments.
Kinoxis Therapeutics is a biotechnology company that develops a range of novel therapeutic compounds.
Aldatu Biosciences is the leader in adaptive PCR diagnostics for global health and emerging diseases.
MaMome uses microbiome analysis and ML to improve maternal health by detecting high-risk pregnancies early.
Orlance provides more effective therapeutic and preventive vaccines for a wide spectrum of viral targets.
CUNY SPH delivers online graduate education that prepares students for success in all domains of public health.
Neuroene Therapeutics offers novel small molecule mitochondrial therapeutics for epilepsy, Parkinson's Disease, and mitochondrial disease.
Matter Bio operates as company focus on preserving genome integrity.
National Institutes of Health has invested in 288 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
National Institutes of Health's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Medical Device. The firm invests across 25 different industry categories.
Among tracked funding rounds, ONL Therapeutics received $65.0M in a Series D round. National Institutes of Health's total known invested capital is $1.3B.
National Institutes of Health's average investment size is $6.6M across its portfolio of 288 companies.
Recent National Institutes of Health portfolio additions include HQ Science Ltd., Sparian Biosciences, NextStep Robotics, Brixton Biosciences, YoungHeartValve. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors